Skip to main content
Premium Trial:

Request an Annual Quote

Volpara Solutions, Ambry Genetics Form Breast Cancer Management Alliance

NEW YORK — Volpara Health Technologies said on Wednesday that its Volpara Solutions subsidiary has signed an agreement to link its cancer screening and practice management platform with Ambry Genetics' program for identifying high-risk breast cancer patients.

Under the terms of the deal, Volpara's Aspen Breast software for medical practice management will include an online ordering process for Ambry's genetic tests. Meanwhile, Volpara's Density software for assessing volumetric breast density will be included in Ambry's Comprehensive, Assessment, Risk, and Education (CARE) program, which uses risk assessment models and genetic testing to identify high-risk women and guide future screening and treatment decisions.

Additional terms were not disclosed.

About a year ago, Wellington, New Zealand-based Volpara Health Solutions acquired Lynnwood, Washington-based Medical Reporting Systems, which developed Aspen Breast. Aliso Viejo, California-based Ambry is a unit of Japan's Konica Minolta.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.